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Abstract 
Historically, patient activism has played a great part in shaping the drug approval 
process. Today, aided by developing web technologies, patients are once again seeking increased 
involvement in their medical care. Their desire to be involved is manifesting in the development 
of patient-run clinical trials, where patients, with the aid of online health-oriented social 
networks, are testing the safety and effectiveness of new drugs. While these trials are not 
currently recognized as valid, scientifically rigorous endeavors and are not accepted by the FDA 
as evidence of the safety and effectiveness of new drugs, small changes in trial structure can 
make these patient initiatives a meaningful part of the drug development process. This paper 
examines the structure and challenges of patient-run clinical trials in the context of the drug 
development and approval process and suggests an point-of-care design alternative as a way to 
address the concerns aroused by such patient-led studies. Ultimately, the paper concludes that the 
enormous social value of such studies should not be ignored, and that the medical, scientific, and 
regulatory communities should work with patients in helping them designing reliable studies 
responsive to their needs that can become a meaningful part of the drug development and 
approval process.   1 
Introduction 
  Drug approval in the United States has been heavily shaped by patient activism. A 
product of the twentieth century, relevant legislation and Food and Drug Administration (FDA) 
regulations resulted in increasingly tight restrictions on marketing new drugs until the 1980s, 
when patients’ desire to take charge of their medical care and their concern with the length of the 
approval process led to a rapid reversal in direction. Prior to the twentieth century, drug 
regulation was in the purview of state and local governments.
1 The first major federal legislation 
governing the marketing of new drugs was the Food and Drug Act of 1906. The Act did not 
require pre-market approval and manufacturers could market a new drug as long as it complied 
with official standards for strength and purity.
2 Following the Elixir Sulfanilamide incident in 
1937,
3 Congress passed the Federal Food, Drug, and Cosmetic Act (FD&C Act) of 1938. The 
new law required that a manufacturer show that the drug is safe prior to marketing.
4 FDA review, 
however, remained minimal as the law required pre-market notification rather than approval.
5 As 
long as a manufacturer notified the FDA of its intent to market a new drug and the Agency did 
not respond within sixty days, the drug could go on the market. The next act of Congress came in 
                                                 
1 For a detailed account of drug regulation history in the United States, see Jeffrey Levi, Unproven AIDS Therapies: 
The Food and Drug Administration and ddI, in BIOMEDICAL POLITICS, 9, 11 (Kathi E. Hanna ed., 1991). 
2 Id.   
3 In 1937, a pharmaceutical company in Tennessee created a new, liquid version of sulfanilamide, a drug used to 
treat streptococcal infections. The company created the liquid version by dissolving the known drug in diethylene 
glycol—a solvent that is commonly used in antifreeze and was quickly revealed to be highly toxic to humans. Since 
the Food and Drug Act of 1906 did not require pre-market safety testing, however, the new formulation’s safety was 
never assessed before the drug was released on the market. About a month after the release of the drug, reports of 
deaths linked to its use began to circulate. Although the FDA acted quickly to retrieve all outstanding prescriptions 
of the drug, more than 100 people, mostly children, had died before the drug was completely recalled. See Sharon B. 
Jacobs, Crises, Congress, and Cognitive Biases: A critical Examination of Food and Drug Legislation in the United 
States, 64 FOOD & DRUG L.J. 599, 604, 2009.    
4 Levi, supra note 1. 
5 Id.    2 
1962 and was a response to the thalidomide crisis in Europe.
6 While the drug’s effects in the 
United States were minimal since the FDA declined to approve it, between 10,000 and 20,000 
children in 46 countries suffered severe deformities as a result of the medicine. Congress 
responded by enacting the Kefauver amendments to the FD&C Act, requiring that manufacturers 
demonstrate the safety and efficacy of drugs prior to marketing.
7 The Act also instituted pre-
market approval by the FDA. This requirement led to the development of lengthier and more 
complex clinical trials, typically comprising three phases, and weeding out the vast majority of 
tested compounds.
8  
  Clinical trials attracted much attention and came under intense political scrutiny in the 
1980s as the length and complexity of the drug approval process became increasingly frustrating 
for patients. Particularly, FDA was encountering difficulties in striking a balance between 
protecting patient safety by demanding comprehensive clinical trial data prior to approval and 
getting potentially life-saving drugs to the market quickly enough. Patient advocacy 
organizations, seeking to empower patients and involve them in their own care, expressed 
concerned with the lack of access to medicines during the lengthy testing process, the failure to 
include women and minorities in clinical trials, and the scarce access to trial results during and 
after testing.
9 The AIDS community gave rise to the most vocal patient organizations at the time 
and the pressure these activists created transformed the nature of clinical trials as well as the 
                                                 
6 Thalidomide, developed by a small German company, was originally marketed as an antibiotic. Although it 
disappointed as such, the drug became known for its sedative properties and the quickly became a blockbuster. 
Various forms of the compound were used to treat nervousness, coughs, and most notably, nausea due to pregnancy. 
In 1961, reports of a significant increase in birth defects linked to the use of thalidomide began to circulate. Women 
who had used the drug during pregnancy frequently gave birth to brain damaged and severely deformed children. 
Due to the discrepancy between the prevalence in side effects in animal studies and human use, the drug was never 
approved in the United States, however over 2.5 million tablets were distributed to more than 1,000 physicians and 
patients before trials were halted in 1962. See Jacobs, supra note 3, at  608-09. 
7 Id. See also Levi, supra note 1 
8 Id. at 12-13.  
9 See ARTHUR A. DAEMMRICH, PHARMACOPOLITICS: DRUG REGULATION IN THE UNITED STATES AND GERMANY, 96-
101(2004).   3 
institutional setting for access to experimental drugs, showing how actively involved patients can 
be in their own care.   
  FDA regulations at the time required that new drug applicants submit data from two well-
controlled clinical trials. AIDS patients challenged trial structure by questioning selection criteria, 
the use of placebo control, and the prohibition against taking other drugs while participating in 
trials.
10 In addition to engaging in direct conversation with regulators, patients challenged the 
clinical trial landscape by carrying out trials of their own. Community-based trials became 
increasingly popular, while patients formed “buying clubs,” making experimental compounds 
available to anyone who wanted them.
11 In effect, activists forced regulators to acknowledge 
clinical trials as a way to access life-saving medicine and to adjust the drug approval process 
accordingly.
12 Profound changes in clinical trial structure followed. In 1988 the FDA announced 
a change in regulations allowing the use of historical data rather than denying some patients the 
use of a potentially effective drug in a trial involving placebo or other treatment.
13 Also in 
response to pressure from patients, the FDA created a “parallel track,” allowing patients who 
were otherwise unable to participate in a full clinical trial to access to the experimental drug.
14 
FDA also sped up the clinical trial process by beginning to use surrogate endpoints in assessing 
the effectiveness of AIDS drugs instead of relying exclusively on long-term survival.
15 
                                                 
10 Id.  
11 See Gina Kolata, Private Doctors Testing AIDS Drugs in Novel Approach, N.Y. Times, July 9, 1989 at A1 
(discussing the prevalence of community-based trials of AIDS medications). See also PETER S. ARNO AND KARYN 
FEIDEN, AGAINST THE ODDS: THE STORY OF AIDS DRUG DEVELOPMENT, POLITICS, AND PROFITS, 71-73, 207-15 
(1992) (discussing underground tests of trichosanthin, a Chinese cancer and abortion drug also known as Compound 
Q, thought to be a potential cure for AIDS).  
12 See generally Thomas C. Merigan, You Can Teach an Old Dog New Tricks: How AIDS Trials are Pioneering 
New Strategies, 323 NEW ENGLAND J. MED. 1341 (1990) (describing the structural changes taking place in AIDS 
clinical trials as a result of the efforts of the AIDS Clinical Trials Group—a partnership of patients, advocates, and 
clinical investigators).  
13 Daemmrich, supra note 9, at 98. 
14 Id. See also Levi, supra note 1 (exploring the emergence of the “parallel track” system and its implications for the 
drug approval process).  
15 Merigan, supra note 12, at 1342.   4 
Additionally, activist pressure led pharmaceutical companies and physicians to start designing 
trials with broader entry criteria and make efforts to give participants more information on 
interim findings.
16  
  Patient activism in the 1980s and 1990s transformed the nature of clinical trials. Patients 
sought greater involvement in their care, seeking the choice to undertake a course of treatment 
even if it has yet to receive FDA approval. The advocacy tactics employed by the AIDS 
community were extraordinarily effective in achieving regulatory and cultural reforms and 
allowing patients to have a strong voice in their treatment. Yet, the reforms in the 1980s did not 
end the debate. Despite these regulatory changes, terminally ill patients are once again becoming 
discontent with what they perceive to be a sluggish and rigid drug approval system that does not 
focus sufficiently on allowing access to life-saving medication. A new wave of patient activism 
is on the rise, and it brings the potential for further productive and lasting regulatory changes. 
  One of the factors that allowed patient activism in the 1980s and 1990s to be a successful 
reform tool was that the main actors—members of the AIDS community—were unusually 
unified by the gravity of the crisis they were facing. This allowed individuals to organize easily 
and efficiently, and to exert collective pressure that the regulatory system of the time could not 
withstand. While today’s patient activism is not brought on by such a crisis, emerging 
technologies are rapidly fulfilling the unifying role necessary to make patients and advocates 
participants in the regulatory process.  
The advent of advanced communications technologies brought on by Web 2.0 
developments have resulted in the formation of patient communities focused around common 
conditions, interests, and causes. Health-oriented social networks are allowing patients from 
around the globe to connect with others with similar conditions, discuss treatment options and 
                                                 
16 Daemmrich, supra note 9.    5 
ideas, and harvest collective knowledge, while seeking to become more involved in their own 
treatments. The slow development of new treatments and therapies is once again coming to the 
forefront of drug regulation, and frustrated patients, supported by online communities, are taking 
matters into their own hands.  
A striking example of patient activism is the advent of patient-run clinical trials. Recently, 
patients have attempted, with varying success, to perform underground trials of promising 
treatments with very limited medical involvement.
17 This development, coupled with the 
capabilities that new technologies provide, presents a great opportunity for drug regulators and 
the pharmaceutical industry to once again improve the drug approval process. Drug approval is 
currently an incredibly costly and lengthy affair. Recent estimates suggest that the development 
of a new drug requires between ten and fifteen years and costs between $802 million and $2 
billion.
18 Most of these costs are incurred during the clinical trial stage. The price of performing 
several phases of clinical testing, involving sometimes thousands of patients in varying 
geographic locations,
19 has been estimated at $467 million,
20 in addition to $97 million
21 for 
post-release monitoring upon which FDA approval is sometimes conditioned.  
  If the medical community can make effective use of newly developed technologies and 
increased patient involvement, drug development costs may be significantly reduced and 
approval time shortened, while allowing patients necessary access to potentially life-saving 
medicines. While patient-run clinical trials have been largely underground and unsupervised 
                                                 
17 See e.g., Catherine Arnst, Health 2.0: Patients as Partners, Businessweek, December 4, 2008 (exploring a lithium 
carbonate patient-run trial on the PatientsLikeMe website); Helen Pearson, Cancer Patients Opt for Unapproved 
Drug, 446 NATURE 474 (2007) (exposing the use of an unapproved small molecule by cancer patients).  
18 Joseph A. DiMasi et al., The Price of Innovation: New Estimates of Drug Development Costs, 22 J. HEALTH ECON. 
141, 167 (2003). See also Mark S. Boguski et al., Repurposing with a Difference, 324 SCIENCE 1394, 1394-95 (2009) 
(analyzing the cost of drug development). 
19 See PETER BARTON HUTT ET AL., FOOD AND DRUG LAW: CASES AND MATERIALS, 624-98 (3d ed. 2007) for a 
detailed description of the FDA regulatory process.  
20 DiMasi, supra note 18, at 165. 
21 Id. at 172-73.    6 
affairs to date, therefore yielding no data that the FDA is willing to consider, they can be re-
designed in a scientifically rigorous way sufficient to collect the safety and effectiveness data 
needed for approval and may supplement, or even entirely replace, the expensive and 
cumbersome company-run trials.  
This paper explores the potential of patient-run clinical trials to transform the drug 
development process.  Part I of the paper discusses the technological developments that have led 
to increased patient interest and involvement in their medical treatment. It focuses on the 
development and function that health-oriented social networks have played in inciting patient 
activism and explores the functionality that these networks have made available to their users. 
This part also examines two examples of patient-run trials as well as the concerns that these trials 
have raised in the scientific and medical community.  
Part II of the paper focuses on the regulatory side of the drug development process, 
examining FDA requirements for approval, the necessary safety and effectiveness showing, as 
well as the structure of clinical trials that FDA currently finds acceptable in making that showing. 
Part III examines the costs and benefits to society of patient-run clinical trials and offers 
suggestions in resolving the issues that such trials present. The section suggests ways for 
restructuring the trials in order to make them scientifically rigorous and allow them to fit more 
comfortably into the FDA regulatory framework. Part IV offers concluding remarks.  
I. Health 2.0 and Patient-centered Medicine 
  Traditionally, healthcare in the United States has conformed to a top-down model: 
doctors have served as a source of information, and primary decision-makers, while relatively 
uninformed patients have passively followed doctors’ orders without having much real input in   7 
their treatment.
22  Technological advances, however, are making great strides in empowering 
patients and allowing them to take charge of their medical care.
23 Specifically, communications 
capabilities resulting from the use of Web 2.0 technologies are giving patients the opportunity to 
easily interact with others with similar conditions, allowing them to harness collective 
knowledge and become informed about their illnesses.
24 Patients can also easily access accurate 
and up to date medical information, and even personally track the progression of their disease 
and assess the effectiveness of various treatments.
25 As a result, duties that have traditionally 
belonged strictly to the physician are being democratized. 
Health 2.0
26, as the recent phenomenon has come to be known, is characterized by “the 
use of social software and its ability to promote collaboration between patients, their caregivers, 
medical professionals, and other stakeholders in healthcare.”
27 They key driving force is the 
belief that patients should have greater insight and input into the medical information that they 
produce. Using available tools on the Internet, thousands of patients are choosing to take an 
active role in their medical care every day.
28  
                                                 
22 Catherine Arnst, Health 2.0: Patients as Partners, BUS. WK., December 4, 2008.  
23 Id.  
24 For a discussion of Web 2.0 technologies’ effect on patient care, see Melanie Swan, Emerging Patient-Driven 
Health Care Models: An Examination of Health Social Networks, Consumer Personalized Medicine and Quantified 
Self-Tracking, 6 INT’L J. ENVTL. RES. PUB. HEALTH, 492, 495 (2009); JANET SARASOHN-KAHN, CAL. HEALTHCARE 
FOUND., THE WISDOM OF PATIENTS: HEALTH CARE MEETS ONLINE SOCIAL MEDIA  (2008). See also Arnst, supra 
note 22. 
25 Swan, supra note 24. See also Jamie Heywood, Chairman, PatientsLikeMe, TEDMED 2009 Presentation: The 
Big Idea My Brother Inspired (Oct. 2009), available at 
http://www.ted.com/talks/jamie_heywood_the_big_idea_my_brother_inspired.html. 
26 A closely related term, Medicine 2.0, is also frequently used in literature. Because of the ever-evolving nature of 
the field, academics and practitioners have not reached a consensus on the exact parameters of either term, so the 
two tend to be used interchangeably. See generally Benjamin Hughes, Indra Joshi, and Jonathan Wareham, Health 
2.0 and Medicine 2.0: Tensions and Controversies in the Field, 10 J. MED. INTERNET RES.  e23 (2008). 
27 Sarasohn-Kahn, supra note 24, at 2.  
28 Recent studies indicate that as of 2008 the Internet is rivaling physicians as a source of health information. 
Between sixty and eighty percent of Americans use the tools available online to find health information. See 
Sarasohn-Kahn, supra note 24, at 3. See also Letter to the Editor, The Power of Social Networking in Medicine, 27 
NATURE BIOTECHNOLOGY 888, 890 (2009).   8 
  An aspect of the Health 2.0 revolution with profound implications for medical care has 
been the formation of health-oriented social networks.
29 Health-oriented social networks are 
websites similar to Facebook and MySpace, thematically organized around a variety of health-
related topics.
30 A network can be general, containing information about a wide variety of 
ailments, or specific—focused on one or a few related conditions.
 31 There are several services 
commonly offered by health-oriented social networks, including emotional support and 
information sharing, virtual contact with physicians and healthcare professionals, quantified self-
tracking, and access to clinical trials.
 32 Each website may offer one or a combination of these 
services.
33  
  The most basic service found on the majority of health social networks is emotional 
support and information sharing. Patients can find information relevant to their conditions, 
ranging from quantitative and qualitative data posted by other users with similar ailments, to 
research citations.
34 By visiting these websites and becoming a part of the online communities, 
patients experience emotional support in knowing that they are not alone in their suffering and 
also by actively doing something—creating a profile, sharing information, educating themselves 
about their condition—to take charge of their health.
35 Additionally, by participating in such 
health-oriented communities, patients are able to take advantage of the collective knowledge of 
the group, which is often “smarter than its smartest members.”
36  
                                                 
29 Sarasohn-Kahn, supra note 24, at 3. 
30 Swan, supra note 24, at 495.  
31 Id.  
32 Id. 
33 Id. at 501.  
34 Id. at 496.  
35 Id.  
36 Sarasohn-Kahn, supra note 24, at 5.   9 
  A second service offered by health-oriented social networks is the ability to interact with 
physicians online.
37 Services can be free or fee-based and patients can pose questions to specific 
doctors or the medical community at large.
38 The inquiries can be public, and therefore 
accessible to all community members, or private, such that only the patient posing the question 
and the physician to whom the question is addressed have access to the exchange.
39 The 
willingness of physicians to participate in such patient care is quite surprising. The common 
belief has been that doctors would not be willing to participate in a healthcare model of that 
eliminates face to face contact with patients for fear of legal repercussions. However, in reality 
many doctors are willing to answer patients’ questions, recommend treatments, and even provide 
tentative diagnoses (accompanied by the appropriate disclaimers) using health-oriented social 
networks, and are reaping reputational and other benefits as a result.
40 This informal doctor-
patient interaction outside of the sterile environment of the doctor’s office is making patients 
active participants in their care, and transforming the role of doctors from arm’s length experts to 
collaborators.
41  
  Yet another service offered by health-oriented social networks that has been instrumental 
in helping patients engage in drug trials is quantified self-tracking: “the regular collection of any 
data that can be measured about the self such as biological, physical, behavioral or 
environmental information.” This functionality consists of data entry capabilities on the web 
related to conditions, symptoms, treatments, and any other relevant information that patients can 
track.
42 The website then displays the data on the patients’ profile and, subject to privacy 
                                                 
37 Swan, supra note 24, at 497. 
38 Id.  
39 Id. at 497, 509.  
40 Id.at 497. 
41 Id. at 498. 
42 Id.   10 
controls, makes it accessible to other community members.
43 Some websites further aggregate all 
data of patients with common conditions, making it possible to create predictive models for 
disease progression and treatment success.
44 Users can input their own data or use a wearable 
device with automated data collection capabilities, which uploads the relevant data to the 
network without further patient involvement.
45 While the former method is currently much more 
common, as wearable data collection devices continue to develop and become more affordable, 
automated uploading will likely become more common. It holds holds great promise in ensuring 
data accuracy and authenticity since it essentially eliminates any patient interaction with the raw 
data.      
A social network that has recently attracted a great deal of attention is PatientsLikeMe.
46 
This website, focused on neurodegenerative conditions, is organized into disease-based 
communities and offers all three services discussed above. Patients can not only obtain 
information and connect with others in similar health situations, but also have access to robust 
quantified self-tracking capabilities.
47 Patients can record their symptoms’ severity and 
progression as well as their treatments, drug regimens, dosages, and other relevant information. 
The site then converts the data into easy to analyze graphs and progress curves, allowing patients 
to track drug efficacy and side effects on themselves and other community members.
 48   
While this website is enormously useful to patients, it has also served a very important 
function for the pharmaceutical industry. Firstly, PatientsLikeMe anonymizes collected patient 
data and, with patient consent, sells it to pharmaceutical companies, universities, and research 
                                                 
43 Id. 
44 Id. See also Heywood, supra note 25. 
45 Id. at 509-12. 
46 www.patientslikeme.com (last visited April 11, 2011).  
47 Editorial, Calling All Patients, 26 NATURE BIOTECHNOLOGY 953, 953 (2008).  
48 Id.   11 
facilities.
49 Companies then use these cheaply and efficiently acquired data to inform their drug 
development process, reaping significant savings from not having to finance a study and collect 
the data themselves.
50 Moreover, frequently, especially in the case of rare diseases, the data are 
simply not available anywhere else.
51  
Social networks also offer pharmaceutical companies a solution to one of the main 
problems companies encounter in conducting clinical trials—recruitment. A third of all trials fail 
to recruit a single patient.
52 Fewer than twenty percent are completed on time, with much of the 
delays attributable to difficulties in recruiting patients.
53 Health-oriented social networks 
aggregate patients with the same condition in the same place and thus provide an ideal 
recruitment environment. Drug manufacturers no longer have to approach individual doctors 
hoping to convince them to refer patients to a clinical trial. Instead, they can simply visit a social 
network focused on their condition of interest and provide information directly to the relevant 
consumers.
54 In fact, in 2008 Novartis used PatientsLikeMe to recruit participants for its multiple 
sclerosis clinical trial, estimating that the new recruitment method was able to speed up the 
1,200-patient study by several months and save the company several million dollars.
55  
While health-related social networks provide pharmaceutical companies with significant 
efficiencies in clinical trial recruitment, patient involvement in clinical trials need not stop there. 
Perhaps the most significant cost-saving tool that health-oriented social networks might be able 
to offer to drug developers is the possibility of patient-run clinical trials. While underground use 
                                                 
49 Malorye Allison, Can Web 2.0 Reboot Clinical Trials, 27 NATURE BIOTECHNOLOGY, 895, 896 (2009).  
50 See Sarasohn-Kahn, supra note 27 at 12. 
51 Arnst, supra note 22.  
52 Allison, supra note 49 at 895.    
53 Id.  
54 Id.  
55 Swan, supra note 24 at 500. For a discussion of clinical trial recruitment models that are capable of resulting in 
significant savings for pharmaceutical companies by utilizing health-oriented social networks see Allison, supra 
note 49 at 899.     12 
of unapproved medicines by patients has been historically problematic,
56 quantified self-tracking 
capabilities are making it conceivable that patients may one day be able to conduct a 
scientifically valid clinical trial. While the idea seems far-fetched and problem-ridden at present, 
the medical community has already witnessed the first attempts at such studies.  
The first such trial took place on PatientsLikeMe and was entirely coordinated by 
network members with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s disease. 
The study was inspired by a publication in peer-reviewed medical journal, reporting that the 
mood-stabilizing drug lithium carbonate may delay the progression of the disease.
57 Lithium 
carbonate is only FDA-approved for the treatment of mood disorders in the United States, but 
determined patients were able to get it prescribed by their doctors off-label.
58 The trial was 
coordinated by a retired engineering professor from the United States, and a Brazilian computer 
systems analyst, both ALS patients and members of the online community.
59 The two recruited 
over 200 ALS patients worldwide to take a specified dose of lithium and answer standardized 
questions meant to gauge participants’ symptoms and disease progression.
60 PatientsLikeMe 
provided the tools necessary for data aggregation and analysis.  
Figure 1 provides PatientsLikeMe’s graphical representation of the aggregated trial data. 
The default display provides the dosages taken (Figure 1(a)), the duration of the treatment 
(Figure 1(b)), the side effects experienced by participants (Figure 1(c)), and the perceived 
effectiveness of the drug (Figure 1(d)). Additionally, graphical representations can be expanded 
to show the data associated with individual trial participants in the selected category (Figure 2), 
                                                 
56 See Arno & Feiden, supra note 11 for discussion of underground testing of Compound Q.  
57 Antonio Paparelli et al., Lithium Delays Progression of Amyotrophic Lateral Sclerosis, 105 PROC. OF THE NAT’L 
ACAD. OF SCI. 2052 (2008) 
58 Patient-run Drug Trials Defy Medical Establishment, FOX NEWS, Nov. 26, 2008, 
http://www.foxnews.com/story/0,2933,458009,00.html.  
59 Id.  
60 Id.    13 
and their full lithium carbonate history (Figure 3). Unfortunately, the data seem to have shown 
that the drug does not actually slow the progression of ALS and many patients have stopped 
taking the medication since.
61  
 
 
 
 
 
 
Figure 1(a): Medication dosages taken by PatientsLikeMe trial participants.
 62  
                                                 
61 Id.  
62 PatientsLikeMe lithium trial, http://www.patientslikeme.com/als/treatments/show/777-lithium-carbonate (last 
visited Apr. 10, 2011).   14 
 
Figure 1(b): Length of lithium carbonate treatment.
63  
 
 
Figure 1(c): Severity and nature of side effects experienced by trial participants.
64  
 
                                                 
63 Id. 
64 Id.   15 
 
 
Figure 1(d): Reported effectiveness of the experimental drug.
65  
 
 
 
 
Figure 2: The individual profiles of all participants are accessible by clicking any data 
parameter in the default graphical display.
66 
 
                                                 
65 Id. 
66 Id.   16 
 
Figure 3: Each patent’s entire history with the particular treatment can be accessed through the 
patient’s profile.
67  
 
 
A similar patient-led initiative occurred in the context of cancer treatments. In 2007, 
Canadian scientists reported that dichloroacetate, (DCA), exhibited promising anti-cancer 
properties.
68 The study reported that the compound shrunk tumors in rats with no apparent side 
effects.
69 DCA has long been the subject of clinical trials for mitochondrial diseases in humans, 
but has yet to be approved even though it has been relatively safe.
70 Additionally, since the 
compound is not novel, it cannot be patented, so there is little interest by pharmaceutical 
                                                 
67 Id. 
68 S. Bonnet et al., A mitochondria-K+ Channel Axis is Suppressed in Cancer and its Normalization Promotes 
Apoptosis and Inhibits Cancer Growth, 11 CANCER CELL 37 (2007).  
69 Id. 
70 Helen Pearson, Cancer Patients Opt for Unapproved Drug, 446 NATURE 474 (2007).   17 
companies in exploring the molecule’s effect on cancer in humans.
71 Frustrated with this lack of 
action, Jim Tassano, the owner of a pest-control and marketing company in California, decided 
to take the matters into his own hands. He came across the Canadian rat study while researching 
alternative cancer therapies to help a dying friend. Teaming up with a chemist, he worked out a 
way to synthesize the drug and started two websites. At the first one, buydca.com, persons could 
buy the DCA that Tassano synthesized, labeled for veterinary use.
72 The second site, 
thedcasite.com,
73 provides patients with information on DCA, as well as the ability to report their 
progress though the website’s chat room or by email. The website is rather rudimentary and does 
not provide the data aggregation and analysis tools available on PatientsLikeMe but many 
patients have reported their results to the site. Ultimately, the FDA, determined that Tassano was 
selling the unapproved compound with the suggestion that it is a cancer treatment and forced him 
to shut down the buydca.com website.
74 The second website, however, is still operational and in 
addition to providing the latest information on DCA, continues to track the progress of patients 
still using the treatment.    
While patient-run trials have the potential to supplement, or even replace the expensive 
company-run trials used in obtaining FDA approval if structured correctly, several significant 
issues need to be addressed before that becomes a plausible option. Both the PatientsLikeMe and 
the DCA studies received strong criticism for failing to meet rigorous scientific standards and 
were generally not accepted by the medical community.
75 Unlike properly structured clinical 
trials, the studies were neither controlled, nor double-blind, which makes it difficult to discern 
                                                 
71 Id. 
72 Id. In the United States, drugs labeled for veterinary use are regulated more loosely than human drugs. Food, Drug, 
and Cosmetic Act §§ 512-573, 21 U.S.C. §§ 360b-60ccc-1 (2008).  
73 www.thedcasite.com (last visited April 11, 2011).  
74 Linda Geddes, Illegal “Cancer Drug” Website Shut Down, NewScientist, July 27, 2007.  
75 Arnst, supra note 22.    18 
placebo effects and assess drug effectiveness with any level of confidence.
76 Further, the studies 
were fraught with self-reporting bias, the tendency of participants to be influenced by other 
patients and not report their symptoms objectively.
77 Moreover, relying on the Internet as a data-
collecting tool gives rise to verification issues—both trials lacked a mechanism for ensuring that 
the participants were who they claimed to be and that the data they contributed was accurate.
78 
Lastly, since these studies were undertaken by patients and were conducted largely without 
medical supervision, there is a serious concern about patient safety, especially in the case of 
DCA, which is not FDA approved for any uses.
79 Scientists are concerned that if participating 
patients develop harmful side effects because of the insufficient medical involvement in the 
patient-led trials, the drug would develop a bad reputation and would deter the efforts to perform 
a proper, physician-lead clinical trial.
80 While these patient-led initiatives hold great promise, 
some fundamental changes in their structure are needed before they can fit into the existing FDA 
drug approval framework and supplement or replace expert-run clinical trials.  
II. The FDA Approval Framework 
  Since 1938 new drugs have had to undergo some form of pre-market review by the FDA 
before being released on the market. The 1938 the FD&C Act required pre-market notification, 
but no pre-market approval by the Agency. Prior to marketing a drug, a sponsor submitted a New 
Drug Application (NDA) to the FDA, and unless the Agency affirmatively disapproved the 
application within sixty days, the drug could be marketed. The 1962 amendments to the FD&C 
Act changed this dynamic. Following the passage of the amendments, no drug could be marketed 
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unless the FDA has found it to be safe and effective for the given indication. Pre-market 
approval is required for chemical entities introduced on the market for the first time, as well as 
already approved drugs, sought to be marketed for new indications.
81   
The approval process is long and expensive, accounting for about half of the cost of drug 
development.
82 The clinical investigation of a new chemical entity can take as many as ten years, 
and for every 5,000 chemicals screened, five will proceed to clinical testing, and one will receive 
final approval.
83 In order to secure FDA approval, the sponsor must submit to the Agency data 
indicating, by substantial evidence, that the drug is safe and effective under the criteria 
established by section 505(d) of the Act.
84 Such data is most frequently obtained through 
extensive clinical trials, conducted at numerous sites throughout the country, and sometimes 
abroad. Section 505(a) of the FD&C Act, however, prohibits the shipment of new drugs in 
interstate commerce unless they have been approved as safe and effective by the FDA.
85 In order 
to facilitate testing and the collection of data, the Act permits the Agency to exempt a drug from 
the 505(a) prohibition for the limited purpose of conducting clinical investigations by “experts 
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qualified by scientific training and experience”
86 to investigate the safety and effectiveness of the 
drug.
87  
Prior to conducting a clinical investigation on human subjects, all new drugs are required 
to go through the Investigational New Drug (IND) process.
88 The initial step is obtaining 
approval by the Institutional Review Board (IRB) of the institution where the trial will be 
performed.
89 Institutional Review Boards’ function is to guard the rights and welfare of trial 
participants before and during clinical trials. IRBs are necessarily a part of a research institution, 
and must be composed of at least five members of varying backgrounds and affiliations.
90 The 
IRB is responsible for approving the trial prior to its commencement, as well as continuous 
monitoring of the study, and approving any changes in research activity, unless the changes are 
necessary to “eliminate apparent immediate hazards to human subjects.”
91 In order to approve a 
clinical investigation, the IRB must determine that the risks to subjects are reasonable in relation 
to the anticipated benefits to subjects and the importance of the expected knowledge; the risks 
are minimized by using sound research design; the selection of subjects is equitable, and 
informed consent is sought from each participant in the study and appropriately documented.
92 
While the FDA can waive the requirement for IRB review,
93 absent a waiver, the Agency can 
decline to consider clinical trial data collected without IRB approval and supervision.
94 
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After obtaining IRB review, a sponsor must submit an IND application to the FDA.
95 The 
information required to be submitted in the application is set forth in federal regulations and 
varies depending on the phase of clinical investigation concerned, the drug to be tested, and 
procedures to be employed.
96 The Agency always requires the submission of information 
showing that the drug is sufficiently safe for use in initial clinical studies in humans. If the drug 
has been studied previously, the sponsor may satisfy this requirement by submitting existing 
nonclinical data from in vitro laboratory or animal studies of the compound, or data from 
previous clinical testing and marketing in the United States or another country with a relevant 
population.
97 If the drug has not been subject to prior investigations, the sponsor must conduct 
preclinical studies to evaluate the toxic and pharmacologic effects of the drug.
98 At minimum, 
the FDA requires that a sponsor “(1) develop a pharmacological profile of the drug; (2) 
determine the acute toxicity of the drug in at least two species of animals, and (3) conduct short-
term toxicity studies ranging from 2 weeks to 3 months, depending on the proposed duration of 
use of the substance in the proposed clinical studies”
99 before human trials can be conducted. 
In addition to the preclinical toxicity and pharmacological profiles, an IND must contain 
proposed study protocols. A typical clinical investigation of a previously untested drug consists 
of three sequential phases. Phase I is a small-scale study, usually involving between twenty and 
eighty subjects.
100 Because this phase is the drug’s initial introduction into humans, the studies 
are closely monitored and while they may be conducted in patients, they are usually performed in 
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healthy subjects.
101 The main objective of Phase I studies is to determine the metabolism and 
pharmacologic actions of the drug, and the side effects associated with increasing doses.
102 
Sufficient information about the drug’s pharmacokinetics and pharmacological effects should be 
obtained during this stage to permit the design of a well-controlled and scientifically valid Phase 
II study.
103 Some preliminary effectiveness data can be collected during Phase I studies as well. 
Phase I studies are usually regarded as the safest phase of clinical testing because they begin with 
low doses of the tested drug and are conducted under close medical supervision.
104 Phase II 
studies are intended to evaluate the effectiveness of the drug for a particular indication in patients 
with the disease or condition concerned, as well as to determine the common short-term side 
effects and risks.
105 Phase II studies are usually small, involving up to several hundred patients, 
and are typically well controlled and closely monitored.
106 Phase III studies are performed after 
sufficient evidence suggesting that the drug is effective for a particular indication has been 
gathered. They are expanded, controlled and uncontrolled studies, aiming to obtain additional 
information about “the effectiveness and safety that is needed to evaluate the overall benefit-risk 
relationship of the drug and to provide an adequate basis for physician labeling.”
107 Phase III 
trials tend to be large-scale, long-term studies, involving between several hundred and several 
thousand subjects and aim to determine the effects of the drug in conditions resembling those of 
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its anticipated use.
108 During Phase I clinical trials, the FDA can impose a clinical hold and 
prohibit a study from proceeding or stop a trial that is already in progress if it finds that the drug 
is not sufficiently safe to be tested in humans or that the sponsor has not adequately disclosed the 
risks associated with the study to investigators.
109 In Phase II and Phase III studies the FDA can 
impose a clinical hold for safety reasons, or because the study is defectively designed and will 
not accomplish its stated objectives.
110 
Several decades ago, when the science and practice of drug development limited clinical 
trial size, three phases of clinical investigation were required to gather sufficient safety and 
effectively evidence. Thus, most clinical trials followed the standard three-phase model. Today, 
increased communicational and technological capabilities allow the design of larger clinical 
trials that supply scientific data to a greater degree of confidence. These developments have 
allowed sponsors to seek approval without always adhering to the traditional three phase 
structure. Although the traditional structure is still common, in modern studies the phases 
frequently overlap since there is no specific regulatory requirement that a sponsor conduct all 
three phases in order to secure approval. Providing the Agency with substantial evidence of the 
safety and effectiveness of the drug is sufficient, regardless of the structure of the trial. In fact, 
the Agency has approved drugs following detailed Phase II studies, as well as drugs that have 
skipped Phase II altogether.
111 
An IND can be submitted for one or more phases of a clinical investigation.
112 It must 
include a protocol for each planned study, including: a statement of the objectives and purpose of 
the study; the names, addresses and qualifications of investigators and others working under their 
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supervision, as well as the names and addresses of the research facilities involved and the 
supervising IRB; the criteria for patient selection and exclusion and an estimate of the number of 
patients involved in the study; a description of the design of the study including the control 
strategy and methods used to minimize bias; the method for determining doses to be 
administered as well as the maximum dosage and duration of each subject’s exposure to the drug; 
description of the observations and measurements to be made during the study; and a description 
of the clinical procedures, laboratory tests and other measures taken to monitor the drug’s effect 
and minimize risk.
113  
The detail required in these disclosures varies according to the phase of the study that the 
IND pertains to. Less detail is required in INDs pertaining to Phase I studies.
114 Such disclosures 
typically provide only an outline of the investigation, the number of subjects, a dosing plan and 
duration of the study, and safety exclusions.
115 Only the elements of the study that are critical to 
its safety are described in detail.
116 Modifications of the study design, unless they impact safety, 
are reported to the FDA in the sponsor’s annual report.
117 Phase II and Phase III protocols, on the 
other hand, describe all aspects of the study in detail.
118 The FDA encourages sponsors to design 
study protocols in such a way that deviations from the study design are built into the protocol. 
Any additional protocol amendments must be submitted to the FDA before changes in the study 
can be implemented, unless the changes are necessary to “eliminate an apparent immediate 
hazard to subjects.”
119  
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Once the IND has been submitted, the Agency has thirty days to review it. The FDA 
reviews INDs pertaining to all phases of a clinical trial to ensure that the trial is sufficiently safe 
for the participating subjects.
120 A reviews of an IND pertaining to Phase II and Phase III studies 
also includes an assessment of the scientific quality of the trial, and the likelihood that the 
investigation will yield data sufficient to meet the approval requirements of § 505(d).
121  Unless 
the Agency disapproves an IND within thirty days of its submission, the clinical trial may begin. 
The FDA has set forth standards, defining what constitutes a well-controlled clinical 
trial.
122 The regulations define a number of criteria that investigators must meet in order for the 
Agency to recognize the results of a trial as substantial evidence of effectiveness. Although the 
substantial evidence need not necessarily come from a trial, in practice such studies are the 
primary basis for drug approval, making compliance with FDA’s criteria particularly important.  
Firstly, there must be a clear statement of the objective of the investigation and the 
proposed methods for analyzing results.
123 The study must also be able to provide a quantitative 
assessment of the drug’s effectiveness by utilizing an appropriate control mechanism.
124 
Acceptable controls include placebo concurrent control, dose-comparison concurrent control, no 
treatment control, active treatment concurrent control, or historical control.
125 Many modern 
studies involve a combination of these control methods, especially when the severity and nature 
of the illness make the use of placebo or known treatment controls ethically suspect. 
Additionally, subject selection methods must ascertain that subjects indeed have the disease or 
condition being studied, or are otherwise qualified to participate in the trial.
126 The method of 
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assigning participants to treatment and control groups must be designed to minimize bias and 
create roughly comparable groups in terms of patient variables such as gender, disease severity 
and progression, and use of other treatments.
127 Most studies accomplish this by using a 
randomized assignment method, where patients are randomly assigned to a trial arm, much like a 
lottery, however other methods are possible. Investigators must also take measures to minimize 
bias on part of both subjects and observers.
128 This is most frequently done through double 
blinding, where neither the patients, nor the persons administering the drug know which group is 
the control and which is a treatment group. In order to provide meaningful results, the study must 
also define the methods that will be used to assess subjects’ response to the treatment, including 
the variables that will be measured, the methods for measuring those variables, and the criteria 
used to assess patients response.
129 The analytical methods employed to assess the effects of the 
drug must be statistically valid and must take into account the comparability of the different arms 
of the study.
130 In addition to these general criteria, FDA regulations set forth good clinical 
practices (GCP) principles, providing examples and detailed guidance on addressing a variety of 
issues that may arise at any stage of the drug approval process.
131 
Another important aspect of study design is the intensity of quality control and on-site 
monitoring.
132 While intense on-site monitoring to ensure high data quality is typical of industry-
sponsored trials, the FDA has expressed willingness to be flexible in assessing quality control. In 
particular, and in accordance with international norms, the Agency has emphasized that 
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monitoring of trials should be fact-specific and dependent on factors such as trial design, size, 
and complexity.
133 If a sponsor is able to ensure quality control though means other than close 
on-site monitoring—by close review of documentation or extensive pre-trial planning with 
investigators, for example—and the trial conforms to good clinical practices, the FDA has 
generally been willing to grant both initial and new indication approvals.
134 
Even well-controlled trials that conform to good clinical practices, however, are not 
without concerns. For a number of reasons, a clinical trial may lead to results that are 
inconclusive, or worse yet, misleading. For instance, despite the best efforts of investigators, a 
clinical trial may be subject to undetected systematic biases that may lead to erroneous 
conclusions.
135 Additionally, the results obtained at any single investigation site may not be well 
generalizable because of influence of site-specific or investigator-specific factors that are not 
truly characteristics of the general population.
136 Lastly, while small, there is a non-negligible 
possibility that indications of effectiveness were obtained purely by chance.
137 Thus, the FDA 
normally seeks independent substantiation of trial results and generally requires at least two 
adequate and well controlled clinical trials to recognize effectiveness.
138 In situations where data 
pertaining to a drug are particularly convincing, however, data from one adequate and well-
controlled clinical investigation may suffice.
139 There are three main situations where a single 
clinical trial or alternative evidence may provide substantial evidence of effectiveness to support 
a given indication.  
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In some cases, the effectiveness of a product may be demonstrated by extrapolation from 
existing clinical studies.
140 This is most frequently applicable for drugs already on the market 
that are seeking approval for a new indication, rather than entirely new products. For instance, 
the effectiveness of alternative formulations of an existing drug may be demonstrated by 
evidence of bioequivalence to the approved formulation.
141 The effectiveness of modified-release 
dosage forms may be extrapolated from immediate-release forms on the basis of 
pharmacokinetic data linking the two.
142 Lastly, effectiveness information of one dose, dosage 
regimen, or dosage form may be used to approve another one based on pharmacokinetic data 
alone, provided that blood levels and exposure are not very different.
143 Sometimes, when the 
agency concludes that a disease progresses sufficiently similarly in children and adults, it may 
approve the use of the drug in children without requiring additional clinical trials.
144  
Another situation where the FDA may not require multiple clinical trials in order to 
approve a drug occurs when the demonstration of effectiveness by a single study of a new use is 
substantiated by reliable data from related studies.
145 Studies in other populations or in other 
phases of the disease can be particularly helpful in this context. Additionally, if the FDA has 
approved the drug for use on its own, a single clinical trial will usually be sufficient to support an 
effectiveness finding for the drug in combination with other therapies.
146 The FDA may also 
approve a drug on the basis of a single clinical trial if the drug has been proven effective in 
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closely related diseases or in less closely related diseases where the general purpose of the 
therapy is sufficiently similar.
147  
This previous two pathways to approval are more likely to be useful for drugs that are 
already on the market and are simply seeking approval for new indications. A third pathway to 
approval that may be appropriate for entirely novel compounds is the use of a large multicenter 
study that, due to its size and structure, produces particularly persuasive results. In order to 
constitute substantial evidence of effectiveness, the study must be large and conducted at 
multiple centers, with patients distributed approximately evenly across test sites. Additionally, 
approval is more likely for studies conducted on a large number of diverse patients, improving 
the generalizability of the findings to the general population. Additionally, for studies 
constructed to include several endpoints involving different events, a sufficient showing of 
effectiveness may be found where the drug is proven effective on more than one endpoint. The 
standard for approval, however, is high. In order for the FDA to find sufficient evidence of 
effectiveness, the data obtained from the single multicenter study has to be extremely persuasive 
and the FDA is still cautious to consider the possibility of an erroneous result.
148 
A vital component to ensuring that the FDA will recognize a clinical trial as well-
controlled and therefore the success of an IND or an NDA is early, effective communication 
between the sponsor and the Agency. Resulting from an agreement between the FDA and the 
pharmaceutical industry in conjunction with the 1997 reauthorization of the Prescription Drug 
User Fee Act (PDUFA),
149 the FDA set forth a guidance outlining the three types of meetings 
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possible between the Agency and sponsors of PDUFA products.
150 Type A meetings are ones 
urgently needed for an otherwise stalled drug development program to proceed.
151 Those 
meeting occur within thirty days of the sponsor’s request.
152 Type B meetings are pre-IND 
meetings, certain end of-Phase I-meetings, or end of Phase II/pre-Phase III meetings.
153 They 
occur within forty-five days of the written request. Type C meetings are any other meetings 
pertaining to the development and review of a human drug.
154 Those meetings occur within sixty 
days.
155 The timeframes for these meetings have frequently been criticized as exceedingly long 
and costly, especially when follow-up meetings may be necessary, which is frequently the 
case.
156  
Additionally, the FDA Modernization Act of 1997 added section 505(b)(5)(B) to the 
FD&C Act, requiring the Agency to meet with sponsors who make a reasonable written request 
in order to reach an agreement on the design and size of clinical trials that will be used as a basis 
of an effectiveness claim for a new drug.
157 Such meetings occur within forty-five days of the 
sponsor’s request and any agreements reached during the meeting are set forth in writing and are 
binding on the Agency’s review division unless the sponsor fails to follow the agreed-upon 
protocol, the relevant data presented by the sponsor is found to be false or incomplete, or the 
“director of the review division determines that a substantial scientific issue essential to 
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determining the safety or efficacy of the drug has been identified after testing has begun.”
158 The 
agreed-upon protocol can also be altered with the written agreement of the sponsor and the 
FDA.
159 Meetings pursuant to § 505(b)(5)(B) have become known as Special Protocol 
Assessments, and are not available once a clinical trial has begun. Although the sponsor can 
request a meeting with the FDA and an evaluation of a commenced study at any time, once a 
trial has begun, the meeting is not subject to the forty-five day timeframe set forth in the Act and 
the results of the evaluation are not be binding on the Agency’s review division. It is important 
that sponsors take advantage of these opportunities to communicate with the FDA frequently and 
candidly. Addressing the Agency’s concerns before clinical testing has begun can result in 
significant cost savings from having to perform follow-up clinical studies or avoiding a clinical 
hold due to deficient study design once the clinical trial has begun.  
In sum, clinical trials are complex creatures that must comply with many requirements 
before being accepted as valid evidence of safety and effectiveness. It is no wonder that many 
people dedicate their entire careers to designing and running clinical trials. The legal, scientific, 
and statistical terrain is complicated at best, and a certain minimum level of expertise is 
necessary in order to perform a clinical trial that the scientific community and the FDA are 
willing to recognize as valid and reliable. Yet, patients seem intent on challenging these norms 
every day. While patients are not expert clinical investigators, they are experts in experiencing 
the diseases that experimental medications are attempting to treat. The pharmaceutical and 
scientific communities should acknowledge this unique expertise and embrace and harness 
patient initiative and wisdom to design the next generation of more efficient clinical trials.  
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III. Clinical Trials 2.0 
A.  The Challenges 
While patient-run clinical studies have enormous potential to supplement or even replace 
expensive clinic-based trials in some contexts, the efforts that we have seen to date present a 
series of problems that prevent them from serving that function. Trial sponsors must address 
these challenges before such trials can become acceptable to the scientific and regulatory 
communities.  
The first significant issue that these trials face is that they are, as a general matter, 
insufficiently scientifically rigorous to be accepted as evidence of safety and effectiveness. The 
trials have been uncontrolled, relying on patients’ abstract account of the drug’s effectiveness or 
lack thereof. Essentially, these trials have had a single treatment arm, and no control group of 
any sort. Effectiveness, however, is necessarily a relative determination, and unless the results 
produced by the experimental treatment are compared to something—placebo, a known 
treatment, or historical data—the trial deviates from good clinical practices as defined by the 
FDA and the medical community and makes it difficult to make a conclusive effectiveness 
determination with any level of confidence, especially where complicated biological systems are 
involved. To make matters worse, patient-run studies have not employed any bias reducing 
mechanism such as blinding. All participants in the trials’ single treatment arm have been aware 
that they are receiving the active experimental drug—once again a significant deviation from 
good clinical practices. This lack of blinding makes it challenging to differentiate genuine 
treatment effects from placebo effects and reduces reliability of the data and therefore the trial’s 
value as a source of evidence for effectiveness.     33 
In addition, in the studies available to date, patients have played the role of study subjects 
and investigators simultaneously. The current structure has left it up to patients to make and 
record observations about the progress of their disease and their response to the investigational 
treatment. This, combined with the fact that aggregate raw data and results are available to 
patients during the course of the study, gives rise to self-reporting bias. Patients are less able than 
neutral, trained observers to record observations and results objectively to begin with. Coupled 
with the access to others’ observations during the course of the trial, patients are likely to 
subconsciously seek to conform to others’ experience and are likely to report less accurate and 
unbiased data. This self-reporting bias is the reason that observing investigators that come in 
close contact with study participants are usually not made aware of trial results until after the 
trial has concluded.  
Another major concern brought on by these trials is data verification. PatientsLikeMe and 
thedcasite are open to anyone who wants to participate. Although PatientsLikeMe requires that 
users create a profile and disclose certain information before they can join the online community 
and take advantage of the website’s full capabilities, patients can provide fairly minimal 
information that does not necessarily reveal their identity. On the other hand, members of 
thedcasite need not disclose any information at all, since the site accepts submissions by email or 
via its blog. In essence, in these two studies it has been impossible to determine with any degree 
of certainty whether patients are entering accurate and reliable data, or whether they even are 
who they purport to be. This anonymity is contrary to good clinical practices as a big part of 
ensuring that trial results are valid and reliable is proper patient selection. Investigators must 
ensure that trial participants are properly qualified for the trial and actually have the condition 
that the experimental drug is expected to treat. This is difficult to do without actual contact with   34 
patients, and nearly impossible without a robust identity verification mechanism. Additionally, 
the anonymity and ease of participation give rise to fraud concerns. One can imagine without too 
much trouble that a pharmaceutical company who is betting its existence on the success of the 
tested drug can find ways to enter fraudulent data and skew the results of the trial. Unless there is 
a way to monitor and control participation and verify patients’ identity, these concerns are a 
major obstacle to obtaining reliable and trustworthy data in patient-run trials.   
The medical community is also concerned about patient safety. Normally, trials are 
conducted under close medical supervision, by clinicians who are well familiar with the drug’s 
potential side effects and in centers that are equipped to deal with possible complications. This is 
clearly not the case with patient-run trials. In fact, both the PatientsLikeMe trial and the DCA 
trial were characterized by very limited medical involvement of any kind. Naturally, the concern 
is that medical oversight is necessary since patients are not normally able to recognize and deal 
with sometimes serious, yet subtle, side effects on their own. Additionally, without the prior 
approval of an IRB and formally signed informed consent prior to the start of the trial, it is not 
clear whether patients understand how risky the experimental therapy is, what side effects they 
might expect to experience, and how to address any complications that occur as a result of their 
participation in clinical trials.  
Moreover, in the case of internet-based clinical trials, patients are disclosing significant 
amounts of personal information and storing it online. While online platforms are what is making 
patient-run trials in the first place, they give rise to strong privacy concerns. Without the 
involvement of an accredited institution, patients’ information is essentially available for all the 
world to see and use as it sees fit. It is not clear who is responsible for safeguarding data and 
protecting patients’ privacy. Moreover, as is the case with the lack of informed consent, it is not   35 
clear that patients understand the risks they take by opening their health information to the world. 
For instance, while disclosing ailment details online can be enormously helpful to the patient 
community, the information is also readily available to employers, who may tacitly take it into 
account when making employment decisions. While this is does not necessarily rule out patient-
run trials as a valid clinical model, it is something that patients should be aware of and should 
actively consider when deciding whether to join an online community and participate in such a 
trial.  
Lastly, the medical and scientific communities are concerned that if an experimental 
treatment causes serious side effects in patient-run trials, it would be difficult to determine 
whether the severity of the incident is due to the drug itself or to an essentially incompetently 
conducted trial due to the lack of medical involvement. Such complications, on the other hand, 
might give an experimental treatment a bad reputation and lead to reluctance to perform a clinic-
based trial, even if closely monitored. In essence, scientists are concerned that patient-run trials 
gone wrong would deter the scientific community from running properly designed trials and 
potentially developing a valuable medicine.     
B.  The Solution: Designing a New Trial 
The concerns with patient-run trials hosted by health-oriented social networks largely 
stem from the decentralized nature of the studies and the lack of medical involvement that is 
characteristic of these endeavors. While the current design of these trials is not optimal, changes 
in study structure can alleviate many of the anxieties that the medical and scientific communities 
have expressed, and transform these patient-run initiatives into legitimate tools for collecting 
reliable clinical information.    36 
A possible change that would enhance the reliability of clinical data collected in the 
course of patient-run trials is requiring physician involvement. Yet, while some physician 
oversight is critical to ensuring a scientifically rigorous trial, a clinic-based setting is not. Rather, 
a more efficient and cost-effective way of accomplishing the goal of reaching out to the medical 
community is a shift to a point-of-care system, where the trial is administered by each 
participant’s individual treating physician. In fact, researchers have recently been successful in 
using point-of-care randomized studies to collect comparative effectiveness data for already 
approved drugs.
160 This model can be further expanded beyond a comparative effectiveness 
study to test new indications for approved drugs, as well as drugs that have never been on the 
market before.   
In this novel hybrid clinical trial system, patients would still be the ones initiating studies 
based on information released by the scientists, doctors, pharmaceutical companies, or other 
patients. Entrepreneurial patients would continue to use health-oriented social networks as an 
organizational tool, designing the trial parameters with input from others, and collecting and 
storing data online. While each health-oriented social network is somewhat different, some are 
very robust and capable of providing different tools capable of addressing a particular study’s 
needs. PatientsLikeMe, for example, has a permanent staff of modelers and engineers, giving it 
the ability to be flexible in the tools it develops and to be maximally responsive to patients’ 
needs. Recognizing the fact that no two clinical trials are the same and that major variations 
could result depending on what the experimental drug is and how it is to be administered, 
networks that are capable of tailoring their resources to each individual study are the optimal 
platform for such patient-run trials.  
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While there seems to be no overarching coordination of the design of the trial and each 
treating physician is, in theory, free to perform the trial in his or her own way, properly designed 
study tools can provide some assistance. If the online platform provides tools that incorporate the 
desired trial and monitoring techniques in the types of information that they call for and the way 
they allow it to be entered, such platforms could force doctors to work within specified trial 
parameters, thereby coordinating physician approaches throughout the study. While the argument 
can be made that each physician still has, to some extent, his or her own subjective way of 
evaluating patients and collecting the data called for by the health-oriented social network tools,  
this is true in the clinic-based context as well and is the product of having data collected by 
multiple investigators. While the decentralized nature of patient-run trials may perhaps 
exacerbate this source of error, the decentralization minimizes clinic-specific and undetected 
systematic errors that become significant when a small number of investigators are involved. 
Additionally, standardized study tools that force doctors to work within the same parameters do, 
to a large degree, alleviate this decentralization concern.  
As a practical matter, the point-of-care model is not difficult to achieve. Once enough 
patients in an online community are interested in a potential treatment and the online platform 
has provided them with the appropriate tools for their study, each participating patient would 
approach his or her treating physicians and enlist the doctor’s help in administering the 
experimental treatment and conducting the monitoring required by the trial. This is relatively 
easy in the case of approved drugs whose off-label indication is being tested as physicians can 
simply prescribe the drug for a different use. The case is more difficult for entirely new chemical 
entities since some coordination with the manufacturer would also be necessary in order to 
obtain the experimental compound. Yet, various arrangements, including registering with the   38 
manufacturer and having the new drug delivered directly to the participating physician, can be 
made. Assuming access to the experimental drug however, having agreed to participate in the 
trial, a treating physician would create a profile on the health-oriented social network where the 
study is to be conducted, and be ready to enter data. A doctor could be able to enter data for of 
multiple patients, and patients’ identities need not be revealed online.  
While at first glance this hybrid patient/doctor trial design seems less optimal than clinic-
based trials, a closer examination reveals its many advantages. Firstly, this new model cuts out 
the currently cumbersome and frequently unnecessary clinical trial bureaucracy, which 
frequently results in administrative delays and encounters recruitment issues. These delays, 
responsible for roughly half of the enormous cost of clinical trials,
161 are largely eliminated in the 
patient-run clinical trial context. Moreover, treating physicians frequently already have a 
relationship of trust with their patients and are well familiar with the condition at issue as 
manifested in the particular patient. Since most patients rely on a single treating physician and 
have therefore been in the care of the particular doctor for some period of time prior to 
commencing the trial, the physician is well aware of the patient’s condition and how to 
effectively manage it. Furthermore, treating physicians, especially specialists, are no less 
qualified to treat patients’ ailments then medical professionals at a trial site who are first 
becoming familiar with the patients in the context of the trial. If a new drug with which the 
treating physician is not familiar is being tested, the doctor can be educated on the expected 
outcomes and potential complications by the developer of the drug with some minimal effort, as 
is the case with clinic-based medical investigators. While there may be doubt about whether 
pharmaceutical companies would be sufficiently honest with doctors and willing to disclose 
potentially serious side effects, the same concern is present in the context of clinic-based trials as 
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well. Because of their familiarity with the trial participants, however, treating physicians would 
be more capable of noticing and reacting effectively to minor health setbacks that may go long 
undetected in the larger trial context. Moreover, just as is the case with clinic-based trials, 
pharmaceutical companies have an incentive to be honest and disclose accurate information in 
order to see the trial come to completion. Withholding information might result in premature 
cessation of the trial, or might lead to a bad reputation for the drug and its manufacturer in the 
medical community—an outcome that pharmaceutical companies strive to avoid at all costs.    
Involving treating physicians in patient-run trials also alleviates many of the scientific 
reliability issues that the medical and scientific communities have had with these endeavors. First, 
the trials can be made more scientifically rigorous by including a control group. The control can 
be patients using an alternate treatment, no treatment at all, or even a comparison to relevant 
historical data. There will inevitably be members of health-oriented social networks that do not 
partake in any given trial or who choose to take a different medication and who continue to track 
their condition progress online. Especially if such patients are willing to enlist the help in their 
treating physicians, their data can reliably be used as a control arm of a trial. Since these patients 
have already taken the initiative to join the health-oriented social network and derive great 
benefits from being part of the online community related to their condition, they are likely to be 
willing to share their information and be participate in the trial, if only as a control mechanism.  
Blinding is a more difficult issue to address, since patients, as the ones organizing the 
trial, are by definition aware of the extent of their participation. Yet, not all clinic-based trials are 
blinded either, and just as in cases where ethical considerations prevent the use of placebo or 
alternate treatment, the lack of blinding need not mean that the trial data is entirely without value. 
While the collected data would have to be statistically analyzed with the awareness of the lack of   40 
blinding in mind, the data can still be very useful to the medical, scientific, and regulatory 
communities. Additionally, as technologies continue to develop, blinding mechanisms are 
becoming increasingly within reach
162 and may become the norm in the near future.  
Additionally, physicians’ involvement essentially eliminates the risk of self-reporting 
bias. Objective physicians can perform medical tests and evaluations and record resultant data 
without being influenced by patients’ desire to fit in with the group or experience a particular 
result. While many evaluations performed in the medical office rely on patients’ description of 
their conditions, symptoms, and progress, doctors, based on their training and experience, would 
be able to make assess the credibility of patients and make these observations impartially and in 
conformity with medical norms. Under the new paradigm, the risks associated with patients 
being study participants and investigators at once become essentially moot. Furthermore, online 
platforms can be structured such that patients have access to the interim aggregated data during 
the course of the study, while treating physicians do not. In this way, patients would remain 
aware of their condition—something that patient activists have fought long and hard for—while 
doctors’ medical evaluations would not be biased by premature data exposure. The study design 
is particularly strong where the variables monitored by the study are objectively testable—pulse, 
blood pressure, blood test results—rather than relying on patients’ description and self-
assessment. Even in cases where reliance on self-assessment is necessary, that would also be the 
case in a clinic-based trial which would be subject to the same bias.   
Verification issues are also alleviated by including physicians in the study design. Since 
physicians in the United States and elsewhere must obtain a professional license before they can 
practice medicine, ease of identity regulation is improved. For most conditions, there are many 
fewer physicians than patients and their identity can be ascertained by reference to their medical 
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credential. When creating online profiles, physicians can be asked to provide identifying 
information and if sufficient doubt exists about the identity or qualifications of a physician, a 
central authority—be it a patient representative,
163 the drug manufacturer, or the FDA—can 
perform further verification, ranging from the request to submit additional paperwork to a site 
visit. For doctors based abroad, the FDA can rely on foreign licensing medical authorities to 
authenticate the identity and qualifications of participating physicians. While the Internet’s 
default setting is anonymity when it comes to patients, once identity is linked to a real-world 
credential like a medical license, identity becomes harder to hide or fabricate. Thus, regulators 
can set prerequisite standards of identity verification, and only physicians who are able to make 
the necessary showing would be allowed to participate. Verifying doctor identities would 
certainly be easier than verifying the identity of thousands of anonymous patients worldwide. 
While fraud might still be a lingering concern, given that misconduct could be traced to a 
specific medical professional, the prevalence of fraud should be no more frequent than in clinic-
based trials. 
Point-of-care clinical trials also alleviate some of the privacy and informed consent 
concerns of the medical community. Since physicians are the ones entering the trial data online, 
it is their identities that are necessarily revealed on the web. Patient identities, on the other hand, 
can remain hidden, even as patients’ data is aggregated and displayed online. Of course, many 
patients would choose to reveal their identities in order to retain a sense of belonging in the 
online community. That is not truly an issue, as long as they are doing so voluntarily and having 
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taken into consideration the possible consequences of the disclosure. While the responsibility can 
fall on doctors to discuss this informational challenge with patients, health-oriented social 
networks are perhaps in a better position to lead the conversation. Educational materials on 
privacy can be presented to the consumer when he or she creates an account and again when he 
or she chooses to participate in a trial. These materials should be presented in a way that patients 
are likely to read, and should describe the different privacy options—from disclosing one's 
identity completely, to remaining completely anonymous, and everything in between—and how 
a patient might choose between the available alternatives.  
Health-oriented social networks should also be completely honest about what they do 
with the data that their members generate. PatientsLikeMe, for instance, anonymizes patients' 
aggregate data and sells it to pharmaceutical companies to be used in the drug development 
enterprise. All PatientsLikeMe community members, however, are aware of this use and have 
consented to it. People who find the use objectionable have a choice not to participate. Although 
this may seem somewhat coercive while the given health-oriented social network is the only one 
dealing with a particular disease or condition—if you want to participate in the trial, you have to 
share your data, albeit anonymously—as the field develops and becomes more closely populated, 
competition would likely result in a race to the bottom and a willingness to accommodate users 
and their privacy and information sharing preferences. Additionally, it is worth noting that many 
patients actively choose to share their identities and data in participating in such networks, since 
many of the benefits of participating in such a community are derived from having open, honest 
interactions with others in a similar health situation. No cause for concern exists, as long as 
patients are able to make informed decisions about the handling of the data they produce.   43 
Informed consent with respect to the medical consequences of an experimental treatment 
are traditionally handled by IRBs in the clinic-based context. These Boards are tasked with 
ascertaining that patients are properly informed of the risks that they are undertaking and able to 
make an informed decision about taking part in the treatment. While patient-run trials are clearly 
a patient initiative and it may seem that consent is no longer an issue—patients clearly want to 
do this, therefore they have consented and we no longer have to worry about patient abuses—the 
emphasis must be on providing information rather than just obtaining consent. It is important to 
remember that most patients are not medical experts (though some are), and may not be aware of 
the sometimes serious risks that they are undertaking in joining a clinical trial. This is 
particularly true for patients with chronic or terminal diseases, who are the most likely 
candidates for these trials. Such patients tend to focus on the quantity rather than the quality of 
life, and may be deceived by the promise of a drug that purports to be a cure regardless of the 
side effects that patients may suffer.  
This phenomenon is well illustrated by the DCA trial, where patients were willing to 
ignore serious purity concerns and ingest a compound that was made essentially in a stranger’s 
basement, solely because of its promise as a cure for cancer. While the blind desire to be cured is 
understandable, it is not clear that trial participants were aware of the significant and potentially 
fatal risks that they were undertaking in taking an unapproved drug. Information matters. Having 
that information is vital in order for patients to be able to weigh all the alternatives and decide 
whether they want to take part in an experimental treatment. The answer will not be the same for 
all patients. Many might still have chosen to take DCA, seeing no prospects of better alternatives 
in the near future. However the point is not that the answer needs to be the same for all patients,   44 
but rather that every patient should be able to make the choice that is best for him or her, and that 
can only be achieved through access to sufficient information. 
This is where the involvement of treating physicians becomes especially important. Even 
in the absence of IRB approval, treating physicians can, and should, be required to collect 
informed consent from participating patients. These doctors are knowledgeable enough to be 
able to disclose relevant information and likely know their patients well enough to be able to 
have an honest discussion about the best course of treatment. Since these doctors have no interest 
in the outcome of the trial and their duties are solely to their patients,
164  they are more likely to 
focus on the best interest of the patient and his specific form of treatment. Because of their 
relationship with their patients, these physicians are more likely to make complete disclosure of 
potential side effects and advise patients not to enter a trial if they believe that a different course 
of treatment might be in the patient’s best interest. This is precisely the purpose of informed 
consent.  
If there is serious concern that treating physicians are not providing patients with 
sufficient information, the FDA can require that informed consent documentation be submitted 
along with a new drug application. While IRBs are currently tasked with collecting this 
documentation and providing it to the Agency upon request, in the new patient/point-of-care 
paradigm, pharmaceutical companies may standardize informed consent forms and request that 
they be returned to the company as a condition to providing access to the experimental medicine. 
While this would be more difficult for patients outside of the United States, a reasonable degree 
of success can be expected as long as there is a single source of the experimental compound.  
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Even doctor involvement, however, leaves some challenges unaddressed. While it is 
possible to make patient-run trials scientifically rigorous, it is more difficult to make them fit into 
the current FDA regulatory framework. FDA regulations have been promulgated with a 
centralized, clinic-based framework in mind and are fairly difficult to change. Although the 
Agency has recently tried to be flexible in what data it will accept as substantial evidence of 
safety and effectiveness, further cooperation by the Agency is necessary to make this currently 
developing tool a part of the drug approval arsenal. Firstly, patient-run trials would not be able to 
comply with regulations requiring the pre-trial approval and continuous monitoring by IRBs. 
While these regulations permit waiver by the FDA, the Agency has granted such waivers rarely, 
and certainly not wholesale. This practice would have to be altered if patient-run trials are to be 
are to serve as acceptable sources of evidence. 
Additionally, many FDA regulations envision communication between the Agency and a 
single entity. While this model is reflective of clinic-based trials where there is a single person in 
charge that the Agency can communicate with, it does not accurately reflect the reality of the 
recent patient initiatives. Patient-run trials are decentralized, involve geographically diverse 
participants, and frequently lack a formal administrator distinct from an entrepreneurial patient 
who is engaging in patient recruitment. While FDA regulatory changes could address this strain, 
the current rules are designed to streamline interactions between the Agency and drug developers 
and to ensure a consistent and efficient line of communication between industry and regulators. 
Decentralizing this model is, therefore, probably not the optimal alternative. Instead, 
pharmaceutical companies can should remain involved, and to some extent responsible for 
experimental uses of their medications. Instead of retaining the clunky bureaucracy of an 
experimental clinic, however, a single representative responsible for monitoring the progress of   46 
trials and the development of a drug would probably suffice. This individual would be in charge 
of filing an original IND and registering the clinical trial on clinicaltrials.gov once appropriate. 
Additionally, once sufficient patient interest has been generated, the pharmaceutical 
representative would work to maintain communications with the FDA to ensure that the trial 
design is acceptable to the regulatory community. Additionally, this representative could also 
work with the appropriate online platforms and health-oriented social networks to come up with 
the tools necessary to collect the appropriate data and ensure the uniformity of data collected by 
treating physicians throughout the trial. Since these trials are only relevant where pharmaceutical 
companies are not taking the initiative and engaging in a clinic-based trial, this pharmaceutical 
representative would only become engaged once there is sufficient patient interest to be able to 
conduct a robust trial and collect sufficiently reliable data. 
C.  Are Patient-run Clinical Trials worth the Trouble? 
Given the multiple challenges that stand in the way of patient-run trials, the question 
becomes whether they are worth the trouble. Would it not be better to just carry on the status 
quo, which although slowly and at high cost, does bring valuable drugs to the market? It is the 
author’s hope that this paper has convinced the reader to the contrary. Patient-run trials are a 
valuable drug development tool that, although in its infancy, should not be allowed to remain 
unexplored. They hold great potential to transform the drug approval process as we know it by 
reducing the length of typical clinic-based trials by months, or even years and by leading to 
significant reductions in trial, and subsequently medicine, costs. In addition, allowing patients to 
drive the drug development agenda ensures that a system with limited resources is focusing its 
efforts where there is greatest demand. Patients would no longer be victims of a system where 
promising molecules that cannot be patented fail to be developed because they would not lead to   47 
sufficient profit for manufacturers. Pharmaceutical companies and physicians are not necessarily 
the most attuned to the needs of patient communities. While these actors do have certain 
expertise in creating treatments, to them the problems faced by terminally ill patients amount to 
an investment opportunity or an abstract intellectual challenge respectively. This is markedly 
different from the way a father of three who has just been told that he will slowly lose control of 
his body and likely die within a few years experiences the problem. It makes sense to let this 
father and others like him drive the research agenda. It makes sense to focus healthcare and drug 
development on their needs, rather than on what seems likely to be the most profitable molecule 
available in a pharmaceutical company's arsenal. 
The FDA is charged with maintaining the delicate balance between keeping unsafe drugs 
off the market and allowing patients to access potentially life-saving medicines quickly enough. 
It is a difficult cost-benefit analysis to perform, and a particularly difficult balance to strike in the 
aggregate. The tipping point is different for different patients. The advantage of patient-run trials 
and the point-of-care system that this paper proposes is that each patient, with the advice of his 
own physician, is allowed to perform the cost-benefit analysis on his or her own. The newly 
acquired flexibility allows each patient to pursue a course of treatment that makes sense in his or 
her own particular context. It is unlikely that a headache sufferer would undertake a trial of a 
medication with potentially fatal side effects—they might just resort to taking acetaminophen or 
another currently available medication. On the other hand, the balance may look quite differently 
for a terminally ill patient who must choose between an experimental therapy with potentially 
serious side effects or passively waiting for his time to expire. This flexibility has great social 
value and should be taken seriously by the medical and scientific communities when considering 
the merit of patient-run trials.    48 
Patient-run trials that take place on health-oriented social networks further provide a great 
opportunity to collect well-generalizable data. Since they span large geographic areas, frequently 
extending internationally, and involve patients with a variety of study-related variables, these 
studies are akin to large multi-center studies that FDA is willing to consider independently as 
evidence of effectiveness and safety. Additionally, because of the frequent involvement of 
international patients facilitated by the Internet, patient run trials can help standardize clinical 
trials internationally. The current norm is that in order to obtain approval, a drug manufacturer 
must seek approval in each country independently and must frequently perform studies in each 
country where approval is sought. If patient-run trials are designed in a way that satisfies most 
international regulators, perhaps the need for redundant studies would be eliminated. Although 
the international community has found it difficult to agree on a common set of universal trial 
criteria, this more decentralized model might provide to be the necessary impetus. Particularly 
since the new paradigm is the product of patient creativity and entrepreneurship and does not 
elevate the norms of any single sovereign over others, it may prove to be more politically 
palatable and may lead to much needed international coordination of clinical trials. 
D.  Where do we go from here? 
Patient-run clinical trials are not the answer to all drug development problems. To be 
sure, it will take a dramatic regulatory changes as well as change in the mindset of the scientific, 
medical, and regulatory communities to accept the scientific validity of these studies and to truly 
harness the full potential of this form of patient activism. Patient activists have been enormously 
successful in shaping the course of drug development history and may prove to be successful 
again.   49 
The process will be ostensibly more difficult for novel chemical entities that have never 
been on the market before. The safety concerns there are particularly noteworthy, since very little 
is usually known about an experimental drug prior to the commencement of the clinical trial. In 
order to avoid legal liability, pharmaceutical companies would be eager to retain control of the 
tested compound and would insist on close physician supervision. Still, provided that treating 
physicians are sufficiently educated about the new molecule and its potential side effects, 
patient-run clinical trials are not entirely out of the question. New compounds may still become 
known and popular to increasingly sophisticated patients who keep abreast of medical and 
scientific publications, as was the case with both lithium carbonate and DCA. Once sufficient 
interest has accumulated, a trial is ready to begin. Pharmaceutical companies can, with fairly 
limited involvement, collect scientifically reliable data to test their new compound. While it is 
conceivable that not all drugs would generate widespread interest, pharmaceutical companies 
always have the option of orchestrating a clinic-based trial if they think that it would be more 
favorable to their interests. Also, because of the general lack of data relating to the new chemical 
entity, a single patient-run trial, however rigorous, would probably be insufficient to obtain FDA 
approval. Thus, in this context, clinical patient-run trials are likely to supplement rather than 
replaced traditional clinic-based trials.  
In the case of new indications for already approved drugs, patient-run trials hold even 
greater promise. Since treating physicians can prescribe the drug for off-label use, patients have 
relatively easy access to the drug in various dosages. Additionally, the need to visit a doctor to 
obtain the drug necessarily involves treating physicians in the trial process and makes point-of-
care trials the natural next step. With relatively little coordination between pharmaceutical 
companies, patients, online platform developers, and the FDA, studies can become scientifically   50 
rigorous and a great sources of comparative effectiveness data. Additionally, as technology 
continues to develop, randomization techniques might become possible, making study data even 
more reliable. Even if the FDA refused to accept such studies as independent, well-controlled 
clinical trials, it should at least allow them to supplement clinical trials and accept them as 
supporting information, thereby requiring drug manufacturers to sponsor only one, as opposed to 
multiple trials. The benefits to the drug development process are fairly obvious. 
Lastly, the data collected by patients on health-oriented social networks can be extremely 
useful to pharmaceutical companies in post-approval monitoring. Currently, while 
pharmaceutical companies are required to report adverse events to the FDA, the typical 
mechanism involves patients reporting adverse events to physicians, who in turn may choose to, 
but are not required to, notify the FDA. It is not surprising that in this long chain of reporting, 
information frequently falls through the cracks and remains undisclosed. Although patients may 
choose to report their issues with approved drugs directly to the FDA,
165 this rate of reporting is 
also fairly low. Instead of relying on this unreliable voluntary reporting mechanism, 
pharmaceutical companies can gather adverse event data from health-oriented social networks, 
since the data is already reported and tracked as part of patient-run trials. This saves 
pharmaceutical companies from having to exert separate efforts and resources to perform Phase 
IV trials and gather adverse event data, while providing the FDA with accurate evidence of drug 
safety that can be used to inform subsequent recall decisions.  
IV. Conclusion 
Patient run clinical trials have great potential to supplement, or even replace expensive, lengthy, 
clinic-based trials. While some regulatory changes would be necessary to accommodate this 
developing paradigm, the most important change necessary to make this new model a functional 
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equivalent of clinic-based trials is changing the mindset of the scientific, medical, and regulatory 
communities. While the trials’ current designs give rise to a number of problems, most issues are 
easy to address by incorporating the participation of treating physicians and shifting to a hybrid 
patient-run/point-of-care model. A trial initiated by patients, but conducted by physicians is 
much less problematic and much more likely to successfully gain the acceptance of the medical 
and regulatory communities.  
  Patient-run trials are valuable social tools, allowing the medical establishment to address 
the needs of every individual patient—something that collective cost-benefit analysis as 
performed by the FDA is grossly inadequate at doing. As such, patient-run trials are not only a 
cost-saving mechanism for drug developers, but also a step in the right direction in striking the 
balance between safety and access to life-saving medications. While the scientific and medical 
communities are generally risk-averse and slow to respond to change, they should recognize the 
tremendous opportunity presented by patient-run clinical trials and once again allow patients' 
desire to be in charge of their personal medical care shape the drug development and approval 
process. 
 
  